Correspondence  by unknown
with this point, the primary focus of our report was the incremental
benefit of TEE in the evaluation of patients with S. aureus bacteremia
rather than the management of patients with endocarditis.
In conclusion, we respect the points raised by Guzzo and Simpson;
however, we feel that the use of a validated diagnostic reference
standard, the probable underestimation of endocarditis among ex-
cluded patients and the clinically logical conclusions in our study
emphasize the need to consider TEE early in the evaluation of patients
with S. aureus bacteremia.
VANCE G. FOWLER, JR., MD
Duke University Medical Center
P.O. Box 3824
Durham, North Carolina 27710
E-mail: fowle007@mc.duke.edu
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Propagation Velocity of Left Ventricular
Filling Flow Measured by Color M-Mode
Doppler Echocardiography
I read with great interest the report by Duval-Moulin et al. (1)
regarding to the application of color M-mode Doppler to assessing left
ventricular diastolic function. The report indicated that left ventricular
diastolic dysfunction during coronary angioplasty could be assessed by
the propagation velocity of left ventricular early filling flow using color
M-mode Doppler technique and that this index showed good correla-
tion with an invasive variable, tau. Their method was very similar to,
but not the same as, our method, which was reported in the Journal in
1996 (2). In their discussion, they introduced our method as follows:
“Takatsuji et al. used a derived technique by measuring the interval
between the maximal rate of increase of action potential upstroke
(Vmax) at the mitral level and 70% Vmax in the apical region.” There
are several inappropriate notations in this sentence. In our report, the
propagation velocity was defined as follows:
By changing the first aliasing limit sequentially at intervals of
2 cm/s with the use of the baseline shift, a flow velocity higher
than the aliasing velocity could be displayed in blue within red
filling flow signals. First, we located the point of maximal
velocity around the mitral orifice in early diastole, which was
obtained at the center of the minimized aliasing area. Next, we
changed the first aliasing limit to 70% of the maximal velocity
and located the point nearest to the apex on the aliasing
boundary (which is usually obtained in the mid-left ventricle).
The distance/time ratio, that is, the upward slope of the line
connecting these two points, was measured and defined as the
rate of propagation of peak early filling flow velocity.
First, the authors used the terms “action potential” and “Vmax,”
which were not used in our report, and this terminology might mislead
the readers and prevent appropriate understanding of our method.
Second, we did not measure the “interval” but the “distance/time
ratio”; and third, the second measurement point is not “in the apical
region” but “in the mid-left ventricle.” We have some evidence that the
propagation velocity measured by our method is more accurate than
that measured at the wavefront of filling flow, which was used in their
report. Therefore, if they carefully traced our protocol, I believe that
they would obtain better correlation between propagation velocity and
tau. Nevertheless, we appreciate the authors’ results because their
study enhances the usefulness of color M-mode Doppler for evaluating
diastolic function in many clinical settings.
AKIRA KITABATAKE, MD, FACC
Department of Cardiovascular Medicine
Hokkaido University School of Medicine
Kita-15, Nishi-7, Kita-ku
Sapporo 060, Japan
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Reply
We have taken into account the different points emphasized by
Kitabatake about the report by Takatsuji et al. (1). As Kitabatake
described, color M-mode Doppler allows remarkably effective obser-
vation of diastolic flow as a function of time and of space.
The color M-mode Doppler method has been developed by several
groups, including Takatsuji et al. (1), Stugaard et al. (2) and ourselves
(3,4). The technique shows correlation of the propagation of early
diastolic flows in the left ventricle with hemodynamic data of relax-
ation, especially the index tau.
With regard to the report of Takatsuji et al. (1) we were naturally
interested in their methods and results, which analyze the rate of
propagation of peak early filling flow. However, their study was
published in the Journal during the review process of our study.
Consequently, we added this new information in the revised version of
our manuscript, which may explain why we did not discuss all the
aspects of the interesting report of Takatsuji et al.
Nevertheless, we would like to point out that in contrast to
Takatsuji et al. (1) and Stugaard et al. (2), we preferred to analyze the
flow front wave at the beginning of filling rather than the later events
of the propagation of peak early filling flow to better evaluate the
relaxation process.
1445JACC Vol. 31, No. 6 LETTERS TO THE EDITOR
May 1998:1440–8
Finally, it is obvious that together we agree that color M-mode
Doppler is a new and interesting noninvasive method for the evalua-
tion of diastolic function.
ANNE MARIE DUVAL-MOULIN, MD
Service de Cardiologie
Hopital Henri Mondor
51 Avenue du Marechal De Lattre de Tassigny
94010 Creteil, France
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Is Pharmacologic Cardioversion of Atrial
Fibrillation Really Preferable to
Electrical Cardioversion?
Harjai et al. (1), in a nonrandomized study, conclude that patients
undergoing electrical cardioversion of atrial fibrillation (AF) display a
“greater degree and longer duration” of mechanical atrial dysfunction
than those who convert pharmacologically or spontaneously. The authors
strongly imply that this finding is a result of the mode of cardioversion.
However, examination of their data reveals that this conclusion is unsup-
ported and, indeed, that an absence of effect is more likely.
There are several flaws in the authors’ analyses and logic. We
would first question whether it is valid, in such a small study of
cardioversion of atrial fibrillation, to include patients who spontane-
ously revert to sinus rhythm. Spontaneous conversions often occur in
the first week of the arrhythmia (2). In a group with a median duration
in excess of 1 month, inclusion of spontaneous convertors with pharma-
cologic converters may bias the data in favor of the latter because, as the
authors point out, a duration of AF ,7 to 14 days has been previously
shown to be associated with better postconversion atrial recovery. Indeed,
reference to Table 1 indicates that almost twice as many patients in the
nonelectrical converter group had an arrhythmia duration ,28 days—a
difference that fails to reach statistical significance only on the basis of the
very small numbers in the former group.
The arbitrary division of AF duration into those with a duration
,28 or .28 days is also problematic. Because previous studies have
demonstrated that an AF duration ,14 days is associated with less
depression of postreversion A wave height (3), the authors should have
analyzed the effects of a shorter arrhythmia duration on A wave
recovery. Indeed, the use of AF duration as a continuous, rather than
a dichotomous, variable would have better elucidated the role of
duration of AF on atrial function.
Multivariate analysis is generally accepted as the “gold” standard in
determining whether a variable is truly associated with an outcome.
When adjusted for several other clinical variables (AF duration, left
atrial size and ejection fraction), the authors state that the mode of
cardioversion was not associated with recovery of atrial electrome-
chanical function, yet they seem to ignore this finding and conclude
from “bivariate analysis” that “only the mode of cardioversion was
seen to have any impact on the recovery of atrial function.”
Finally, it is in our opinion, inaccurate to categorize this study as a
comparison between patients undergoing either pharmacologic or
electrical cardioversion. Presumably, many of the patients who subse-
quently underwent electrical cardioversion had been prescribed an
antiarrhythmic agent either in an attempt to convert the arrhythmia or
to maintain sinus rhythm after cardioversion. If this is so, then the
study is predominantly a comparison of patients who responded to
pharmacologic agents with those in whom pharmacologic conversion
failed. Seen in this light, attributing postreversion atrial stunning to the
mode of reversion is inaccurate.
Whether pharmacologic cardioversion of AF produces less atrial
mechanical dysfunction than electrical cardioversion is an interesting
question that may have some bearing on postconversion risk of
thrombus formation. However, the answer to this question will require
a randomized trial of immediate, drug-free electrical conversion
compared with pharmacologic conversion. Failure to convert, either
electrically or pharmacologically, will have to be treated as failure to
recover mechanical atrial function. To retain a high likelihood of
pharmacologic conversion, entry should probably be limited to those
patients with a short (,7 or ,14 days) arrhythmia duration. Only the
results of such a study can give meaningful answers to the question of
whether the atrium really cares how sinus rhythm is restored (4).
RODNEY H. FALK, MD, FACC
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Reply
We agree with Falk and colleagues that a randomized trial of electrical
versus pharmacologic cardioversion would be the best way to assess the
impact of mode of cardioversion on postcardioversion atrial mechan-
ical dysfunction. Although our study (1) was not a randomized trial, it
represents the only attempt so far to address this issue after multivar-
iate adjustment for other clinical variables that could potentially
influence postcardioversion atrial function. Of all the variables tested,
only the mode of cardioversion was seen to have any influence on the
recovery of atrial function. It is noteworthy that the delay in mechan-
ical recovery of atrial function that was associated with electrical (vs.
nonelectrical) cardioversion was significant after adjustment for pa-
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